At the AACR-Industry Roundtable 2026 representatives from academia, patient advocacy, the biopharmaceutical industry, and federal agencies came together to...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO,...
At the AACR Annual Meeting 2025, experts offered strategies on how to overcome the challenges within the oncology drug...
In part 4 of our 2024 Experts Forecast, Paul Workman, PhD, shares thoughts on cutting-edge advances in oncology drug...
It is an exciting era for drug development in oncology. The many discoveries of new molecular targets, coupled with...
Earlier this year, the American Association of Cancer Research (AACR) partnered with Novocure, a global oncology company, to launch...
There has been an explosion in the number of cancer therapeutics and clinical trials in the recent past, owing...
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...
Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...